Literature DB >> 22543950

[The German network for systemic sclerosis (DNSS): current data on diagnostics and therapy].

N Hunzelmann1, T Krieg.   

Abstract

An essential prerequisite for progress in understanding the pathophysiology and the clinical treatment of rare diseases is the national cooperation of specialized centers. The German network for systemic sclerosis (DNSS) is such an interdisciplinary union of hospitals and research centers with a special interest in systemic sclerosis (SSc). A core activity is the patient register of the DNSS which includes over 3,100 patients. It is one of largest national registers of SSc patients worldwide and comprises prospective data on diagnostics as well as primarily therapy of the patients. The register has now proven to be an extremely successful basis for clinical research and basic studies within the framework of international cooperation. The most important results of the cooperation and the register will be presented in this article.

Entities:  

Mesh:

Year:  2012        PMID: 22543950     DOI: 10.1007/s00105-011-2300-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  21 in total

Review 1.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 2.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

3.  Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity.

Authors:  G Szücs; Z Szekanecz; E Zilahi; A Kapitány; S Baráth; S Szamosi; A Végvári; Z Szabó; S Szántó; L Czirják; C György Kiss
Journal:  Rheumatology (Oxford)       Date:  2007-03-23       Impact factor: 7.580

4.  Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres.

Authors:  J Fransen; D Popa-Diaconu; R Hesselstrand; P Carreira; G Valentini; L Beretta; P Airo; M Inanc; S Ullman; A Balbir-Gurman; S Sierakowski; Y Allanore; L Czirjak; V Riccieri; R Giacomelli; A Gabrielli; G Riemekasten; M Matucci-Cerinic; D Farge; N Hunzelmann; F H J Van den Hoogen; M C Vonk
Journal:  Ann Rheum Dis       Date:  2011-07-21       Impact factor: 19.103

5.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 7.  Scleroderma epidemiology.

Authors:  Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

8.  Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors.

Authors:  C Sunderkötter; I Herrgott; C Brückner; P Moinzadeh; C Pfeiffer; J Gerss; N Hunzelmann; M Böhm; T Krieg; U Müller-Ladner; E Genth; E Schulze-Lohoff; M Meurer; I Melchers; G Riemekasten
Journal:  Br J Dermatol       Date:  2009-01-13       Impact factor: 9.302

9.  Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.

Authors:  L G Hanitsch; G-R Burmester; C Witt; N Hunzelmann; E Genth; T Krieg; W Lehmacher; I Melchers; M Meurer; U Müller-Ladner; E Schulze-Lohoff; M Becker; C Sunderkoetter; G Riemekasten
Journal:  Rheumatology (Oxford)       Date:  2009-01       Impact factor: 7.580

10.  Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.

Authors:  Rudolf Mierau; Pia Moinzadeh; Gabriela Riemekasten; Inga Melchers; Michael Meurer; Frank Reichenberger; Michael Buslau; Margitta Worm; Norbert Blank; Rüdiger Hein; Ulf Müller-Ladner; Annegret Kuhn; Cord Sunderkötter; Aaron Juche; Christiane Pfeiffer; Christoph Fiehn; Michael Sticherling; Percy Lehmann; Rudolf Stadler; Eckhard Schulze-Lohoff; Cornelia Seitz; Ivan Foeldvari; Thomas Krieg; Ekkehard Genth; Nicolas Hunzelmann
Journal:  Arthritis Res Ther       Date:  2011-10-21       Impact factor: 5.156

View more
  2 in total

Review 1.  Pharmacology and rationale for imatinib in the treatment of scleroderma.

Authors:  Pia Moinzadeh; Nicolas Hunzelmann; Thomas Krieg
Journal:  J Exp Pharmacol       Date:  2013-04-04

2.  Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.

Authors:  Ralf Ewert; Till Ittermann; Dirk Habedank; Matthias Held; Tobias J Lange; Michael Halank; Jörg Winkler; Sven Gläser; Horst Olschewski; Gabor Kovacs
Journal:  BMC Pulm Med       Date:  2019-11-29       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.